Past studies
Browse through some of our past studies
HN-2
Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Type and Number of Samples
- Prospective
- Matched Fresh Tissue and Whole blood (or PBMCs), 10 subjects
Specific Requirements
- All subtypes accepted
- Subjects confirmed positive for HPV 16for HPV 16
- Samples from biopsies and surgical resections accepted
- Minimum weight of 100 mg resected tumor tissue or at least 3 core needle biopsies (CNBs) per subject
- Minimum of 40 ml whole blood or 40 x 106 PBMCs per subject with at least 70% viability upon recovery
- Subjects confirmed negative for HIV/HCV/HBV
Associated Data Required
- Age, Gender, Ethnicity
- Sample collection date
- HPV 16 expression status
- Sample type (e.g. resection or CNB)
- For whole blood: volume of sample (ml)
- For PBMCs: number of cells per subject
- Tumor stage and grade
- Treatment history (if not treatment-naïve)
- Available mutation status information (e.g. TP53, CDKN2A, PTEN, PIK3CA, and HRAS)
SC-2
Disease
Melanoma
Type and Number of Samples
- Prospective
- 1 subject, matched samples
- Freshly resected tumor tissue (> 1 g) and Whole blood, (> 20 mL, collected in K2 EDTA tubes)
Specific Requirements
- Pathology confirmed diagnosis
- Any stage, Any subtype
- Primary and secondary (i.e. metastatic) tumors accepted
- No recent chemotherapy treatment: subjects must be treatment naïve or must have received chemotherapy more than 6 weeks prior to sample collection
Associated Data Required
- Age, Gender, Ethnicity
- Sample collection date
- Stage (TNM) and grade
- Tumor size and location (if information on metastases is available)
- HIV, HCV and HBV status
HN-1
Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Type and Number of Samples
- Retrospective
- FFPE blocks, 40 subjects
- 5 subjects with Stage I HNSCC
- 5 subjects with Stage II HNSCC
- 5 subjects with Stage III HNSCC
- 15 subjects with Stage IV HNSCC
- 10 subjects with any stage HNSCC
Specific Requirements
- For Stage IV HNSCC: minimum of 10 subjects for which samples were collected from secondary tumor tissue (e.g. lung, liver, skin)
- For any stage HNSCC: samples from recurrent primary tumor tissue
- Subjects for all groups must be positive for HPV 16
- Tumor content ≥ 30%
- Necrosis ≤ 30%
Associated Data Required
- Age, Gender
- Year of collection
- Type of sample collection (primary or secondary site)
- Collecting site (eg. skin, brain, lung, liver)
- Sample type (e.g. resection or biopsy)
- Histological subtype
- Tumor stage and grade
- HPV 16 status
- % tumor and % necrosis per sample
OC-10
Disease
Breast cancer (non-fatty lymph nodes only) / Ovarian Cancer / Cervical Cancer / Uterine Cancer
- Colorectal cancer / H&N cancer /Gastric Cancer / Liver Cancer / Pancreatic Cancer (PDAC)
- Lung Cancer
- Renal cell carcinoma (RCC) / Bladder cancer
Type and Number of Samples
- Prospective
- 20 subjects, matched samples.
- Tumor tissue (minimum of 500mg), Lymph nodes (minimum 300 mg), 2 red-cap whole blood tubes
Specific Requirements
- Lymph nodes to be processed following the protocol provided by the study sponsor to isolate LN-derived Mononuclear Cells (LNs should be tumor free: soft by palpation) - Minimum of 10x106 Mononuclear Cells per case
- Whole blood to be processed to serum
- Therapy Naïve, post-neoadjuvant therapy, at relapse
- 70% recovery (number of cells) and 70% viability at the following steps: post-isolation (PI), pre-freeze (PF), QC (quality control) post-thaw (PT) at provider’s facility
Associated Data Required
- Age, Gender, Ethnicity
- Medical History
- Concurrent disease(s)
- Current medication provided with each patient along with de-identified pathology report
PT-1
Disease
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Type and Number of Samples
- Retrospective
- FFPE blocks, 20 subjects
Specific Requirements
- Metastatic (secondary) tumor tissue resections only
Associated Data Required
- Age, Gender, Ethnicity
- Sample collection date
- Pathological diagnosis with microscopic description (histologic subtype)
- Tumor stage and grade (Gleason scoring)
BUO-9
Disease
Epithelial Ovarian Cancer
Type and Number of Samples
- Prospective
- Matched samples: Freshly resected tumor tissue (> 1 g) and Matched whole blood (> 20 mL, collected in K2 EDTA tubes), 1 subject
Specific Requirements
- Pathology confirmed diagnosis
- Any stage and subtype accepted
- Primary or metastatic tumors accepted
- No recent chemotherapy treatment: subjects must be treatment naïve or must have received chemotherapy more than 6 weeks prior to sample collection tumor subtypes of epithelial origin only
Associated Data Required
- Age, Gender, Ethnicity
- Sample collection date
- Stage (TNM) and grade
- Tumor size and location (if information on metastases is available)
- HIV, HCV and HBV status
BUO-8
Disease
Breast Cancer
- Triple Negative Breast Cancer (TNBC)
Type and Number of Samples
- Retrospective
- FFPE blocks Matched blocks from pre-treatment (biopsy) and post-treatment (resection), 5 sets
Specific Requirements
- Confirmed diagnosis of TNBC (HER2 negative, ER negative, PR negative)
- Any histological subtype and any stage accepted
- Primary and/or metastatic tumors
Associated Data Required
- Age, Gender
- Sample collection date
- Origin/Site of tumor
- ER, PR, and HER2 status
- Tumor Stage (TNM) and Grade
- Treatment history
BUO-7
Disease
Endometrial Cancer
Type and Number of Samples
- Retrospective
- FFPE blocks Matched blocks from pre- and post-treatment, 18 sets
Specific Requirements
- Any histological subtype and any stage accepted
- Primary tumors only for pre-treatment FFPE blocks
- Both primary and/or metastatic tumors accepted for post-treatment FFPE blocks
- Minimum tumor content: 30%
Associated Data Required
- Age, Gender
- Diagnosis with histopathological subtype
- Date of pre-treatment biopsy/resection
- Date of post-treatment biopsy/resection
- Stage (TNM)
- Treatment history
BUO-6
Disease
Breast Cancer
Type and Number of Samples
- Prospective
- EDTA Plasma, 10 subjects
Specific Requirements
- Primary or recurrent cancer
- Subjects who did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
- Recent cancer staging should be within 90 days prior to baseline visit
- Samples from all stages of cancer will be accepted
Associated Data Required
- Age, Gender, Ethinicity
- Sample collection date
- Height (cm), Weight (kg)
- Method of diagnosis (Screening program/Symptoms suggestive of cancer/Following incidental findings/Other-specify)
- Smoking status
- CBC (Complete Blood Count), Hemoglobin level (g/dL), Mean Corpuscular Volume (MCV), Ferritin level
- Presence of comorbidity:Chronic kidney disease, Renal failure • Cirrhosis (if yes – what is the reason? Alcohol, HBV, HCV), Diabetes, COPD, Autoimmune disease (if yes – which?)
- Family history of cancer
BUO-5
Disease
Breast Cancer
Type and Number of Samples
- Retrospective
- FFPE slides, 5 subjects
Specific Requirements
- Stage III or IV only
- Treated or untreated
- Resections and biopsies
- Primary tumors only
- Any histopathological subtype
- Tumor content ≥ 30 %
Associated Data Required
- Age, Gender, Ethinicity
- Sample collection date
- Histological subtype
- Pathological diagnosis
- Tumor stage and grade
- ER/HER2 status
IO-1
Disease
Anti-PD1 Therapy Patients
- Non-Small Cell Lung Cancer (NSCLC)
Type and Number of Samples
- Prospective
- Plasma - 10 subjects
Specific Requirements
- Subjects diagnosed with Non-Small Cell Lung Cancer (NSCLC), Renal cancer or other solid tumors
- Subjects who are going to receive anti-PD1 therapy with prospective clinical follow up
Associated Data Required
- Age, Gender
- Diagnosis
- Sample collection date
IO-2
Disease
Immunotherapy Treated Patients
- Melanoma or Non-Small Cell Lung Cancer
Type and Number of Samples
- FFPE Blocks - 50 subjects
- Prospective
Specific Requirements
- Subjects diagnosed with Non-Small Cell Lung Cancer (NSCLC) or Melanoma
- Immunotherapy treated patients, preferentially with an equal distribution for MSI-H and MSS cases (IHC, Promega or equivalent methodology)
Associated Data Required
- Age, Gender
- TNM staging
- Follow-up status (relapse, survival)
- Date of initial diagnosis
- Sample collection date
- Details of administered immunotherapy
- MSI status and Reference test used for MSI characterization
- Pathological diagnosis (Cancer Type and stage)
- Samples characterization data (total area, total tissue area, and % tumor or tumor area)
IO-3
Disease
Anti-PD1 Therapy Patients
- Non-Small Cell Lung Cancer (NSCLC) - adenocarcinoma subtype
Type and Number of Samples
- Retrospective
- FFPE Slides - 50 subjects
- 3 groups: * Responders to anti-PD1 therapy; * Responders to ati-PD1 therapy relapsing within 6 months of treatment; * Non-responders
Specific Requirements
- Subjects treated with pembrolizumab (Keytruda) or nivolumab (Opdivo) (or other anti-PD1 monoclonal antibodies)
- FFPE samples (preferably surgical resection material) collected within max of 12 months prior to therapy with anti-PD1; other previous treatments are acceptable (radio- and chemo-therapy)
Associated Data Required
- Age, Gender
- Basic pathology data
- Medications and treatments with dates
- At least 12 months clinical follow up data
- Overall survival and progression survival
- Data on relapse
- Sample collection date
IO-4
Disease
Anti-PD1 Therapy Patients
- Renal Cell Carcinoma
Type and Number of Samples
- FFPE Blocks - 10 subjects
- Retrospective
Specific Requirements
- Subjects treated with Pembrolizumab (Keytruda) or nivolumab (Opdivo)
- FFPE blocks (resection or biopsy) collected within 12 months prior to therapy
- Other previous treatments are acceptable
Associated Data Required
- Age, Gender, Ethnicity, Race and BMIN
- Basic Pathological data
- Medications and treatments
- At least 24 months clinical follow up data
- Overall survival and progression-free survival by RECIST criteria
- Data on relapse
IO-5
Disease
Anti-PD1 Therapy Patients
- Non-Small Cell Lung Cancer (NSCLC)
- Subtypes: Adenocarcinoma; Squamous Cell Carcinoma; Large Cell Carcinoma; Clear Cell Carcinoma; Adenosquamous Carcinoma
Type and Number of Samples
- Retrospective
- FFPE Blocks - 90 subjects
Specific Requirements
- Primary tumor
- Subjects without EGFR mutations
- PD-L1 positive cases (cut-off: 1%)
Associated Data Required
- Age, Gender, Ethnicity
- Sample collection date
- Pathological diagnosis with microscopic description and subtype
- Tumor Stage and Grade
- Origin/Site of tumor
- Confirmation of wild type EGFR
- PD-L1 score
- Other IHC available data (i.e. TTF-1, P40, and when applicable: chromogranin A and synaptophysin)
- % tumor and % necrosis per sample
IO-6
Disease
Anti-PD1 Therapy Patients
- Non-Small Cell Lung Cancer (NSCLC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Upper tract transitional cell carcinoma (UTCC)
Type and Number of Samples
- Retrospective
- FFPE Slides - 40 subjects per indication
- Sets of 3-5 FFPE tissue sections
Specific Requirements
- Subjects must have been treated with anti-PD-1 drugs (i.e. Opdivo® or Keytruda®)
- Ideally, 20 % of the subjects respond to anti PD-1 treatment (partial response or complete response)
- Samples from biopsies or surgical resections
- Tissue collected prior to anti-PD1 treatment
- Tissue samples fixed in 10 % Neutral Buffered Formalin (NBF)
Associated Data Required
- Age, gender
- Year of collection
- Pathological diagnosis with microscopic description (histological subtype)
- Tumor stage and grade
- Treatment history and medical outcome post-immunotherapy
IO-7
Disease
Anti-PD1 Therapy Patients
- Non-Small Cell Lung Cancer (NSCLC)
Type and Number of Samples
- Retrospective
- 59 FFPE blocks of PD-L1 TPS between the range 5-20%
- 28 FFPE blocks of PD-L1 TPS between the range 55-70%
Specific Requirements
- Any stage; Any subtype
- FFPE blocks are to be evaluated for expression level (tumor proportion score (TPS)) of Programmed Death Ligand 1 (PD-L1)
- FFPE blocks that allow the cutting of ≥ 50 sections of 4 µm
- Tumor content ≥30%
- Tissue samples fixed in 10% Neutral Buffered Formalin (NBF) between 12 to 72 hours
Associated Data Required
- Age, Gender
- Date of sample collection
- Confirmation of diagnosis along with histological subtype
- PD-L1 TPS score (%)
- Fixation time
IO-8
Disease
Anti-PD1 Therapy Patients
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Carcinoma
Type and Number of Samples
- Retrospective
- FFPE Blocks - total of 50 subjects
- NSCLC Adenocarcinoma ALK positive (N=13)
- NSCLC Adenocarcinoma PD-L1 (SP142) positive (N=7)
- Colorectal Carcinoma MSH2 loss (N=15)
- Colorectal Carcinoma MSH6 loss (N=15)
Specific Requirements
- Any stage; Any subtype
- Tumor % ≥ 25%
- Necrosis % < 40%
- Minimum Slide Yield: 50 cuts
Associated Data Required
- Age, Gender
- Year of collection
- Site/origin of tissues
- Pathology diagnosis
- If primary or metastatic tumor
- Tumor stage, grade
IO-9
Disease
Immune checkpoint inhibitor treatment
- Late Stage Metastatic Melanoma (MM)
Type and Number of Samples
- Retrospective
- FFPE blocks - 20 subjects
Specific Requirements
- Subjects with failed multiple lines of treatment (immune checkpoint inhibitor treatment failure preferred)
- Samples from biopsies or surgical resections
- Samples from primary or secondary (e.g. metastatic) tumors
- Tumor content ≥ 30%
- Necrosis ≤ 30%
- Tissue samples fixed in 10% Neutral Buffered Formalin (NBF)
Associated Data Required
- Age, Gender
- Sample Site (primary or secondary site)
- Sample collection site (e.g. skin, brain, lung, liver)
- Year of collection
- Histological subtype
- Tumor stage and grade
- % tumor and % necrosis per sample
- Patient treatment history
IO-10
Disease
Immune checkpoint inhibitor treatment
- Non-Small-Cell Lung Carcinoma (NSCLC)
Type and Number of Samples
- Retrospective
- FFPE Slides - 20 subjects
- Group 1: Non-responders to immunotherapy (n=10)
- Group 2: Non-responders to EGFR kinase inhibitor treatment (n=10)
Specific Requirements
- Subjects with high expression of PD-L1 (≥ 50% positive tumor cells) as per IHC analysis
- Samples from core needle biopsies or surgical resections
- Tissue samples fixed in 10 % Neutral Buffered Formalin (NBF)
- Group 1: Non-responders to anti-PD-1/PD-L1 drugs (i.e. Opdivo®, Keytruda®, Tecentriq®, Imfinzi® or Libtayo®)
- Group 2: Non-responders to EGFR kinase inhibitors (i.e. Tagrisso®, Iressa®, Tarceva®, Gilotrif®, Conmana®)
Associated Data Required
- Age, Gender
- Year of collection
- Pathological diagnosis with microscopic description (histological subtype)
- Tumor stage and grade
- Treatment history and medical outcome post-therapy
- PD-L1 expression (IHC) data, if applicable
IO-11
Disease
Patients Responders to IO treatment
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Type and Number of Samples
- Retrospective
- FFPE sections - 3 subjects
- Per subject: 5 sections of 5 µm, 10 mm2 surface area
- Per subject: H&E stained image matching the slide set
Specific Requirements
- Subjects must be treated with any immune checkpoint blockade monoclonal drugs (e.g. nivolumab, pembrolizumab etc.)
- Subjects must be responding to anti PD1 treatment (i.e. partial response or complete response)
- Biopsies or resection tissue samples fixed in 10% Neutral Buffered Formalin (NBF)
- Tissue collected prior to anti-PD1 treatment
Associated Data Required
- Age, Gender
- Year of collection
- Pathological diagnosis with microscopic description (Histological Subtype)
- Tumor Stage and Grade
- Site of primary tumor
- Treatment history and medical outcome post-immunotherapy (RECIST)
- Patient Medical History, Medications
LC-02
Disease
Lung Cancer
- Squamous cell lung carcinoma
- Primary lung adenocarcinoma
Type and Number of Samples
- Tissue Microarrays (TMA); total of 1000 subjects
- Squamous cell lung carcinoma (Stages I to IV) : 340 subjects
- Primary lung adenocarcinoma (Stages I to IV): 660
Specific Requirements
- Retrospective
- Main TMA: Adenocarcinioma : 2 cores at the center of tumour + 2 cores at tumour margin including inflammatory cells if observed. For each patient the first 2 cores (600 microns) punched at center + margin have to be placed near each together. Squamous cell lung carcinoma : 3 cores at the center of the tumour
- 2nd MTA block (Replicates): Random location to differ from main block
- General Specification for each TMA: 60-70 cores per TMA. Each core is 0.6mm TMAs prepared for each type of cancer and stage. 30 patients per TMA
Associated Data Required
- Age, Gender
- Diagnostic and medical data
- Stage (TNM, grade), % tumor cells in sample
- Smoking status
- Clinical history including Disease-free survival, Overall survival
LC-12
Disease
Lung Cancer
- Non-Small Cell Lung Carcinoma
- Metastatic
Type and Number of Samples
- Retrospective
- Whole Blood, 11 subjects
Specific Requirements
- Stage IV NSCLC subjects
- Chemotherapy naïve Donors
Associated Data Required
- Age, Gender
- Diagnostic and medical data
- Stage (TNM, grade)
- Medical History and medical out-come
LC-17
Disease
Lung Cancer
- Non-Small Cell Lung Carcinoma
- EGFR mutation positive
Type and Number of Samples
- Prospective
- Plasma, 50 subjects
Specific Requirements
- Patient previously treated or still treated with EGFR Tyrosine Kinase Inhibitor e.g. Gefitinib or Erlotinib
- Responders or non-responders
- Patients treated by TAGRISSO™(Osimertinib) were excluded
- First line or second line of treatment
Associated Data Required
- Age, Gender
- Sample collection date
- Comprehensive pathology and clinical characteristics records
- Smoking history
- Treatment history
LC-18
Disease
Lung Cancer
- Small Cell Lung Cancer (SCLC)
Type and Number of Samples
- Retrospective
- FFPE Blocks, 175 subjects
Specific Requirements
- Stage I to IV
- Primary tumors and secondary tumors
Associated Data Required
- Age, Gender, Ethinicity
- Sample collection date
- Pathological diagnosis with microscopic description
- Tumor stage and grade
- Origin/site of tumor
- Patient Medical History
LC-20
Disease
Lung Cancer
- Non-Small-Cell Lung Carcinoma (NSCLC)
- Adenocarcinoma
Type and Number of Samples
- Retrospective
- FFPE Blocks, 15 subjects
- FFPE Blocks and Matched Plasma, 5 subjects
Specific Requirements
- Patients non-responders or progressors after 2 lines of standard of care (SOC) for the treatment of NSCLC (chemotherapy or biological therapy
- Radiotherapy was excluded as line of treatment accepted
- Biopsies or surgical resections
Associated Data Required
- Age, Gender
- Sample collection date
- Histopathological diagnosis
- TNM stage
- Description of treatment (e.g. chemotherapy protocol or checkpoint inhibitor therapy protocol)
- Treatment history with chronology of treatments and sample collection (i.e. whether sample has been collected before or after treatment)
- Treatment outcome
LC-21
Disease
Lung Cancer
- Non-Small Cell Lung Carcinoma (NSCLC)
- Adenocarcinomas and Squamous cell carcinomas
Type and Number of Samples
- Prospective
- Matched sets of: Flash frozen tumor tissue, Plasma and Whole Blood
- 20 subjects
Specific Requirements
- Biopsy
- Stage I
- Treatment naïve subjects
Associated Data Required
- Age, Gender, Ethinicity
- Sample collection date
- Subject Height (cm) and Weight (kg)
- Diagnosis (cancer type and histological subtype)
- Type of procedure used to obtain definitive diagnosis (e.g. FNA, open lung biopsy surgery)
- Type of procedure used to obtain definitive diagnosis (e.g. FNA, open lung biopsy surgery)
- TNM and stage
- Treatment history
- Mutation/hormonal status when data is available
LC-22
Disease
Lung Cancer
- Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Cancer (SCLC)
Type and Number of Samples
- Prospective
- Plasma, 150 subjects
Specific Requirements
- Subjects that did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
- Recent cancer staging should be within 90 days prior to baseline visit.
- All stages
Associated Data Required
- Age, Gender, Ethinicity
- Sample collection date
- Height (cm) and Weight (kg)
- Diagnostic method (Screening program/Symptoms suggestive of cancer/Following incidental findings/Other-specify)
- Smoking status
- CBC (Complete Blood Count), Hemoglobin level (g/dL), Mean Corpuscular Volume (MCV), Ferritin level
- Existing comorbidity (yes or no): Chronic kidney disease, Renal failure, Cirrhosis (if yes – what is the reason? Alcohol, HBV, HCV), Diabetes, COPD, Autoimmune disease (if yes – which?)
- Family history (cancer in first and second degree relatives)
- Diagnosis – disease type and subtype
- TNM and stage
- Location of metastases (if any)
LC-23
Disease
Lung Cancer
- Non-Small Cell Lung Carcinoma (NSCLC)
Type and Number of Samples
- Retrospective
- FFPE blocks Matched blocks from pre- and post-treatment, 10 sets
Specific Requirements
- All subtypes and all stages
- Primary tumors only
- Both primary and/or metastatic tumors accepted for post-treatment FFPE blocks
- Minimum tumor content: 30%
Associated Data Required
- Age, Gender
- Diagnosis with histopathological subtype
- Date of pre-treatment biopsy/resection
- Date of post-treatment biopsy/resection
- TNM amd stage
- Treatment history
GI-2
Disease
Colorectal Cancer
Type and Number of Samples
- Prospective
- FFPE Blocks and Matched Plasma, 200 subjects
Specific Requirements
- Newly Diagnosed patients with Colorectal Cancer stage IV
- Known KRAS mutation status
- Blood samples collected before treatment
Associated Data Required
- Age, Gender
- Stage (TNM, grade)
- KRAS mutation status
- Treatment History and medical out-come
GI-5
Disease
Gastric Cancer
- Poorly cohesive carcinoma and Normal Adjacent Tumor
Type and Number of Samples
- Retrospective
- Frozen Tissue, 50 subjects
Specific Requirements
- Sample weight > 0.5g
- Sample collected before neoadjuvant therapy or radiotherapy
Associated Data Required
- Age, Gender, Ethinicity
- Sample collection date
- Weight, height, BMI
- Histologic type, Histologic grade, Pathologic staging (TNM)
- Demographic, diagnostic and medical data
GI-7
Disease
Adenocarcinoma of the Esophagogastric Junction
Type and Number of Samples
- Retrospective
- FFPE Blocks, subjects
Specific Requirements
- Stage IIIB or higher
Associated Data Required
- Age, Gender
- Diagnostic and medical data
- Stage (TNM, grade)
GI-19
Disease
Hereditary non-polyposis colorectal cancer (HNPCC)
- Lynch syndrome
Type and Number of Samples
- Retrospective
- FFPE Blocks, 10 subjects
Specific Requirements
- Confirmed loss of MSH6 expression
- Any stage, Any grade, Any histological subtype
- Resections only
- Primary tumors only
- Treated and untreated subjects
Associated Data Required
- Age, Gender
- Year of collection
- Histological subtype
- Tumor Stage (TNM) and Grade
- Method used for confirmation of MSH6 loss of expression
GI-20
Disease
Colorectal Cancer (CRC)
- Esophageal Cancer
- Gastric Cancer
Type and Number of Samples
- Prospective
- EDTA plasma, 50 subjects
Specific Requirements
- Primary or recurrent cancer
- Subjects who did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
- Recent cancer staging should be within 90 days prior to baseline visit.
Associated Data Required
- Age, Gender, Ethinicity
- Sample collection date
- Height (cm), Weight (kg)
- Method of diagnosis (Screening program/Symptoms suggestive of cancer/Following incidental findings/Other-specify)
- Smoking status
- CBC (Complete Blood Count), Hemoglobin level (g/dL), Mean Corpuscular Volume (MCV), Ferritin level
- Presence of comorbidity: Chronic kidney disease, Renal failure, Cirrhosis (if yes – what is the reason? Alcohol, HBV, HCV), Diabetes, COPD, Autoimmune disease (if yes – which?)
- Family history of cancer
GI-22
Disease
Cholangiocarcinoma (CC) (intra-hepatic (IHCC) and/ or extra- hepatic (EHCC))
- Ampullary Papilla Cancer (APC)
- Gallbladder Cancer (GBC)
- Adenocarcinoma
Type and Number of Samples
- Retrospective
- FFPE Blocks, 202 subjects
Specific Requirements
- Any stage, Any grade
- Resections
- Primary tumors and secondary tumors (i.e. metastatic) tumors from bile duct, gallbladder, or ampulla of Vater
- Treated and/or untreated patients
- Minimum tumor content ≥ 30%, Maximum necrosis ≤ 10%
Associated Data Required
Pathological diagnosis with microscopic description (Histological Subtype)
- Age, Gender
- Year of collection
- Pathological diagnosis with microscopic description (Histological Subtype)
- Tumor Stage and Grade
- Site of primary, or secondary tumor (if applicable)